| _version_ |
1860797333840592896
|
| building |
INTELEK Repository
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| date |
2024-08-26 20:51:07
|
| format |
Restricted Document
|
| id |
12292
|
| institution |
UniSZA
|
| internalnotes |
1. Abubakar AR, Simbak NB, Haque M. Adverse drug reactions: predisposing factors, modern classifications and causality assessment. Res J Pharm Tech. 2014;7(9):1091–8. 2. Abubakar AR, Chedi BAZ, Simbak NB, Haque M. Medication error: the role of health care professionals, sources of error and prevention strategies. J Chem Pharmaceut Res. 2014;6(10):646–51. 3. Abubakar AR, Simbak NB, Haque M. Knowledge, attitude and practice on medication use and safety among Nigerian postgraduate-students of UniSZA, Malaysia. Int J Pharmaceut Res. 2014;6(4):104–10. 4. Polasek TM, Lin FPY, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71(5):727–36. 5. Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescrib. 2012;35(3):85–8. 6. Zwart-Van Rijkom JEF, Uijtendaal EV, Ten Berg MJ, van Solinge WW, Egberts ACG. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68(2): 187–93. 7. Bucsa CD, Cazacu I, Farcas AM, Bojita M. The prevalence of potential drug-drug interactions in the therapy of Romanian community pharmacy’s patients. Farmacia. 2012;60(4):510–6. 8. Tari L, Anwar S, Liang S, Cai J, Baral C. Discovering drug–drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics. 2010;26(18):547–53. 9. Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601–10. 10. Kafeel H, Rukh R, Qamar H, Bawany J, Jamshed M, Sheikh R, et al. Possibility of drug-drug interaction in prescription dispensed by community and hospital pharmacy. Pharmacol Pharm. 2014;5(4): 401–7. 11. Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83–94. 12. Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drugdrug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol. 2005;60(5):508–18. 13. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000;13(4):421–3. 14. Bobroff LB, Lentz A, Turner RE. Food/drug and drug/nutrient interactions: what you should know about your medications. Drugs. 2009;(FCS8092):1–10. 15. Kashyap M, Cruz SD, Sachdev A, Tiwari P. Drug-drug interactions and their predictors: results from Indian elderly inpatients. Pharm Pract (Granada). 2013;11(4):191–5. 16. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol. 1998;45(6):539–44. 17. Dubova SVD, Reyes-Morales H, Torres-Arreola LDP, Suárez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico city. BMC Health Serv Res. 2007;7:147. 18. Ismail MYM. Herb-drug interactions and patient counseling. Int J Pharm Pharmaceut Sci. 2009;1(Suppl 1):151–61. 19. Renuka G, Thiruvengadarajan VS, Amruthkumar N, Mahesh K, Madhusudhanchetty C. A review on herb-drug interactions. Int J Pharmaceut Res Dev. 2011;3(3):136–53. 20. Djuv A, Nilsen OG, Steinsbekk A. The co-use of conventional drugs and herbs among patients in Norwegian general practice: a crosssectional study. BMC Complement Altern Med. 2013;13(1):295. 21. Nance G, Bradford R, Grappe F, Suttles T, Twilley B, Coward L, et al. In vitro metabolic investigational studies of herbal-drug interactions leading to predictive clinical outcomes. J Bioequiv Availab. 2013;6(1):1–2. 22. Zhi-Xu H, Thach C, Zhou SF. Clinical herb-drug interactions as a safety concern in pharmacotherapy. J Pharmacol Drug Metabol. 2014;1:1–3. 23. Benni JM, Jayanthi MK, Tubaki BR, Renuka M. Knowledge and awareness of food and drug interactions (FDI): a survey among health care professionals. Int J Pharmacol Clin Sci. 2012;1(4):97–105. 24. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001;52(5): 587–95. 25. Tasneem TSS. Drug-herb interactions. Int J Pharmaceut Chem Biol Sci. 2012;3(1):75–8. 26. Saxena A, Tripathi KP, Roy S, Khan F, Sharma A. Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation. 2008;3(5):198–204. 27. Bland SE. Drug-food interactions. J Pharm Soc Wisconsin. 1998; 14(Suppl 2):S28–35. 28. Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J. 2011;26(2):77–83. 29. Otles S, Senturk A. Food and drug interactions: a general review. Acta Sci Pol Technol Aliment. 2014;13(1):89–102. 30. Pugh MJV, Starner CI, Amuan ME, Berlowitz DR, Horton M, Marcum ZA, et al. Exposure to potentially harmful drug-disease interactions in older community-dwelling veterans based on the healthcare effectiveness data and information set quality measure: who is at risk? J Am Geriatr Soc. 2011;59(9):1673–8. 31. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response. J Pharm Pharm Sci. 2006;9(3):292–306. 32. Kuo TH, Mendonca EA, Li J, Lussier YA. Guideline interaction: a study of interactions among drug-disease contraindication rules. AMIA Annu Symp Proc. 2003;2003:901.
|
| originalfilename |
6592-01-FH02-FP-15-03726.pdf
|
| person |
Adobe Acrobat Pro DC 20.6.20042
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12292
|
| spelling |
12292 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12292 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal application/pdf Adobe Acrobat Pro DC 20 Paper Capture Plug-in with ClearScan 8 1.6 Adobe Acrobat Pro DC 20.6.20042 2024-08-26 20:51:07 6592-01-FH02-FP-15-03726.pdf UniSZA Private Access Drug interaction and its implication in clinical practice and personalized medicine National Journal of Physiology, Pharmacy and Pharmacology In personalized medicine, the appropriate drugs for an individual patient are selected based on the patient’s medical history, diagnostic testing, and genetic information for the purpose of minimizing drug interactions (DIs), side effects, and adverse drug reactions (ADRs) and to obtain the maximum therapeutic benefit. The DI is one of the major problems of pharmacotherapy, which perhaps leads to adverse outcome or therapeutic failure if not properly addressed. In clinical practice, patient safety is likely to improve through the identification of frequently occurring DIs by pharmacist and notifying the other members of the health-care team. Recently, a software was introduced, which detects DIs with good precision; however, this software requires a constant update. Health-care professionals require adequate knowledge and skills on how to identify and avoid DIs to enable them complement the software assessment. Basically, DIs include drug–drug, drug–food, drug–herbal, and drug–disease interactions. These possibilities can be identified from chemical properties, pharmacokinetics, and pharmacodynamics of the drug, patient medical history, concomitant disease, or organ failure. Focusing on DIs will help to reduce drug-related problems, advance the evidence-based medicine, and improve the level of patient satisfaction. Adequate knowledge of drug DIs will enable the health-care professionals to individualize the patient treatment in order to get maximum therapeutic benefit. This script is aimed at describing the various classes of DIs, their causes, and their implications in clinical practice and personalized medicine. 5 5 1-7 1. Abubakar AR, Simbak NB, Haque M. Adverse drug reactions: predisposing factors, modern classifications and causality assessment. Res J Pharm Tech. 2014;7(9):1091–8. 2. Abubakar AR, Chedi BAZ, Simbak NB, Haque M. Medication error: the role of health care professionals, sources of error and prevention strategies. J Chem Pharmaceut Res. 2014;6(10):646–51. 3. Abubakar AR, Simbak NB, Haque M. Knowledge, attitude and practice on medication use and safety among Nigerian postgraduate-students of UniSZA, Malaysia. Int J Pharmaceut Res. 2014;6(4):104–10. 4. Polasek TM, Lin FPY, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71(5):727–36. 5. Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescrib. 2012;35(3):85–8. 6. Zwart-Van Rijkom JEF, Uijtendaal EV, Ten Berg MJ, van Solinge WW, Egberts ACG. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68(2): 187–93. 7. Bucsa CD, Cazacu I, Farcas AM, Bojita M. The prevalence of potential drug-drug interactions in the therapy of Romanian community pharmacy’s patients. Farmacia. 2012;60(4):510–6. 8. Tari L, Anwar S, Liang S, Cai J, Baral C. Discovering drug–drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics. 2010;26(18):547–53. 9. Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601–10. 10. Kafeel H, Rukh R, Qamar H, Bawany J, Jamshed M, Sheikh R, et al. Possibility of drug-drug interaction in prescription dispensed by community and hospital pharmacy. Pharmacol Pharm. 2014;5(4): 401–7. 11. Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83–94. 12. Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drugdrug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol. 2005;60(5):508–18. 13. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000;13(4):421–3. 14. Bobroff LB, Lentz A, Turner RE. Food/drug and drug/nutrient interactions: what you should know about your medications. Drugs. 2009;(FCS8092):1–10. 15. Kashyap M, Cruz SD, Sachdev A, Tiwari P. Drug-drug interactions and their predictors: results from Indian elderly inpatients. Pharm Pract (Granada). 2013;11(4):191–5. 16. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol. 1998;45(6):539–44. 17. Dubova SVD, Reyes-Morales H, Torres-Arreola LDP, Suárez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico city. BMC Health Serv Res. 2007;7:147. 18. Ismail MYM. Herb-drug interactions and patient counseling. Int J Pharm Pharmaceut Sci. 2009;1(Suppl 1):151–61. 19. Renuka G, Thiruvengadarajan VS, Amruthkumar N, Mahesh K, Madhusudhanchetty C. A review on herb-drug interactions. Int J Pharmaceut Res Dev. 2011;3(3):136–53. 20. Djuv A, Nilsen OG, Steinsbekk A. The co-use of conventional drugs and herbs among patients in Norwegian general practice: a crosssectional study. BMC Complement Altern Med. 2013;13(1):295. 21. Nance G, Bradford R, Grappe F, Suttles T, Twilley B, Coward L, et al. In vitro metabolic investigational studies of herbal-drug interactions leading to predictive clinical outcomes. J Bioequiv Availab. 2013;6(1):1–2. 22. Zhi-Xu H, Thach C, Zhou SF. Clinical herb-drug interactions as a safety concern in pharmacotherapy. J Pharmacol Drug Metabol. 2014;1:1–3. 23. Benni JM, Jayanthi MK, Tubaki BR, Renuka M. Knowledge and awareness of food and drug interactions (FDI): a survey among health care professionals. Int J Pharmacol Clin Sci. 2012;1(4):97–105. 24. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001;52(5): 587–95. 25. Tasneem TSS. Drug-herb interactions. Int J Pharmaceut Chem Biol Sci. 2012;3(1):75–8. 26. Saxena A, Tripathi KP, Roy S, Khan F, Sharma A. Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation. 2008;3(5):198–204. 27. Bland SE. Drug-food interactions. J Pharm Soc Wisconsin. 1998; 14(Suppl 2):S28–35. 28. Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J. 2011;26(2):77–83. 29. Otles S, Senturk A. Food and drug interactions: a general review. Acta Sci Pol Technol Aliment. 2014;13(1):89–102. 30. Pugh MJV, Starner CI, Amuan ME, Berlowitz DR, Horton M, Marcum ZA, et al. Exposure to potentially harmful drug-disease interactions in older community-dwelling veterans based on the healthcare effectiveness data and information set quality measure: who is at risk? J Am Geriatr Soc. 2011;59(9):1673–8. 31. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response. J Pharm Pharm Sci. 2006;9(3):292–306. 32. Kuo TH, Mendonca EA, Li J, Lussier YA. Guideline interaction: a study of interactions among drug-disease contraindication rules. AMIA Annu Symp Proc. 2003;2003:901.
|
| spellingShingle |
Drug interaction and its implication in clinical practice and personalized medicine
|
| summary |
In personalized medicine, the appropriate drugs for an individual patient are selected based on the patient’s medical history, diagnostic testing, and genetic information for the purpose of minimizing drug interactions (DIs), side effects, and adverse drug reactions (ADRs) and to obtain the maximum therapeutic benefit. The DI is one of the major problems of pharmacotherapy, which perhaps leads to adverse outcome or therapeutic failure if not properly addressed. In clinical practice, patient safety is likely to improve through the identification of frequently occurring DIs by pharmacist and notifying the other members of the health-care team. Recently, a software was introduced, which detects DIs with good precision; however, this software requires a constant update. Health-care professionals require adequate knowledge and skills on how to identify and avoid DIs to enable them complement the software assessment. Basically, DIs include drug–drug, drug–food, drug–herbal, and drug–disease interactions. These possibilities can be identified from chemical properties, pharmacokinetics, and pharmacodynamics of the drug, patient medical history, concomitant disease, or organ failure. Focusing on DIs will help to reduce drug-related problems, advance the evidence-based medicine, and improve the level of patient satisfaction. Adequate knowledge of drug DIs will enable the health-care professionals to individualize the patient treatment in order to get maximum therapeutic benefit. This script is aimed at describing the various classes of DIs, their causes, and their implications in clinical practice and personalized medicine.
|
| title |
Drug interaction and its implication in clinical practice and personalized medicine
|
| title_full |
Drug interaction and its implication in clinical practice and personalized medicine
|
| title_fullStr |
Drug interaction and its implication in clinical practice and personalized medicine
|
| title_full_unstemmed |
Drug interaction and its implication in clinical practice and personalized medicine
|
| title_short |
Drug interaction and its implication in clinical practice and personalized medicine
|
| title_sort |
drug interaction and its implication in clinical practice and personalized medicine
|